159557-47-8

Basic information

• Product Name: HDH-PHARMA 24737
• Synonyms: HDH-PHARMA 24737;TERT-BUTYL 4-(BENZYLOXY)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 159557-47-8
• Molecular Formula: C₁₇H₂₅NO₃
• Molecular Weight: 291.388
• Mol File: 159557-47-8.mol

Chemical Properties

• Boiling Point: 383.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• PKA: -2.21±0.40(Predicted)
• CAS DataBase Reference: HDH-PHARMA 24737(CAS DataBase Reference)
• NIST Chemistry Reference: HDH-PHARMA 24737(159557-47-8)
• EPA Substance Registry System: HDH-PHARMA 24737(159557-47-8)

Safety Data

• Hazardous Substances Data: 159557-47-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
HDH-PHARMA 24737 is used as an analgesic agent for the treatment of chronic pain. It is favored for its ability to produce pain-relieving effects without inducing the common side effects associated with traditional opioid medications, such as addiction or respiratory depression.
Used in Research Applications:
In research, HDH-PHARMA 24737 is utilized as a selective agonist for the δ-opioid receptor. This selective targeting allows for focused studies on the δ-opioid receptor's role in pain management and the development of novel opioid-based medications with improved safety and efficacy profiles.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-39-0 benzyl bromide 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 100-44-7 benzyl chloride 

Downstream Products

• 872692-22-3 N-(2-ethoxycarbonyl)-L-valine 4-(benzyloxy)piperidide 
• 872692-35-8 N-tert-butoxycarbonyl-L-valine 4-benzyloxypiperidide 
• 872692-21-2 L-valine 4-(benzyloxy)piperidide 
• 76716-51-3 4-(benzyloxy)piperidine 

Relevant articles and documents

Contra-thermodynamic Hydrogen Atom Abstraction in the Selective C-H Functionalization of Trialkylamine N-CH3 Groups

We report a simple one-pot protocol that affords functionalization of N-CH3 groups in N-methyl-N,N-dialkylamines with high selectivity over N-CH2R or N-CHR2 groups. The radical cation DABCO+?, prepared in situ by oxidation of DABCO with a triarylaminium salt, effects highly selective and contra-thermodynamic C-H abstraction from N-CH3 groups. The intermediates that result react in situ with organometallic nucleophiles in a single pot, affording novel and highly selective homologation of N-CH3 groups. Chemoselectivity, scalability, and recyclability of reagents are demonstrated, and a mechanistic proposal is corroborated by computational and experimental results. The utility of the transformation is demonstrated in the late-stage site-selective functionalization of natural products and pharmaceuticals, allowing rapid derivatization for investigation of structure-activity relationships.

EHPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1-42 aggregation for Alzheimer's disease therapeutics

With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (AChE) and beta-amyloid peptide (Aβ) aggregation inhibition. For binding with the catalytic site of AChE, an ester with aromatic group was designed, and for the peripheral site, another aromatic group was considered. And for intercalating amyloid-beta oligomerization, long and linear conformation with a lipophilic group was considered. The synthetic methods employed for the structure with dual action depended on alcohols with an aromatic ring and the substituted benzoic acids, which are esterificated in the last step of the synthetic pathway. We screened these new derivatives through inhibition tests of acetylcholinesterase, butyrylcholinesterase (BChE), and Aβ1-42 peptide aggregation, AChE-induced Aβ1-42 aggregation. Our results displayed that compound 12 showed the best inhibitory potency and selectivity of AChE, and 29 showed the highest selectivity of BChE inhibition. Compounds 15 and 12 had inhibitory activities against Aβ1-42 aggregation and AChE-induced Aβ aggregation. In the docking model, we confirmed that 4-chlorobenzene of 12 plays the parallel π-π stacking against the indole ring of Trp84 in the bottom gorge of AChE. Because the benzyhydryl moiety of 12 covered the peripheral site of AChE in a funnel-like shape, 12 showed good inhibitory potency against AChE and could inhibit AChE-induced Aβ1-42 peptide aggregation.

PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE

[Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

Asymmetric michael reactions on polymeric support: Auxiliary immobilization and stereoselective construction of quaternary stereocenters

Several strategies for the immobilization of a L-valine-derived auxiliary on a Merrifield resin and on poly(ethylene glycol) are reported. The latter is shown to work excellently in asymmetric copper(II)-catalyzed Michael reactions of cyclic β-oxo esters 2 with methyl vinyl ketone (4), yielding the corresponding addition products 5 with quaternary stereocenter in selectivities of 97-99 % ee. The PEG-supported auxiliary 1d can be precipitated from diethyl ether solutions and reused. A sulfur-containing β-oxo ester 2c was prepared in 92 % yield by a DMAP-catalyzed transesterification method in order to detect enamine formation on solid support. The sulfur content can be used as an additional parameter in combustion analysis and therefore, may act as a diagnostic probe for enamine formation. Wiley-VCH Verlag GmbH & Co. KGaA, 2005.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives, linked by a fluoro-substituted alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, are selective agonists of 5-HT1 -like receptors, being potent ago

Benzimidazole derivatives

The invention is directed to substituted benzimidazole compounds which are ligands for dopamine receptor subtypes used in the treatment of the dopamine system.